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1. Introduction  
Under the heading of acute coronary syndrome (ACS), we include myocardial infarction 
with ST segment elevation (STEMI), myocardial infarction without ST segment elevation 
(NSTEMI) and unstable angina (UA). Given the similar pathophysiological mechanisms, 
clinical manifestations, diagnostic and therapeutic algorithm UA and NSTEMI are sorted 
into a common group of ACS without ST segment elevation (NSTE-ACS). ACS is a serious 
clinical disease, which is associated with higher mortality than stable angina pectoris. High 
proportion of patients die of sudden death in the early hours of ACS (especially STEMI), 
before admission to the hospital, therefore it is difficult to assess the real incidence of ACS. 
The incidence of ACS also depends on the sensitivity of the humoral markers of myocyte 
necrosis. The annual hospital admissions rate for NSTE-ACS is estimated from the results of 
registers and surveys about 3 per 1000 inhabitants. The proportion of STEMI represents 
approximately 20% of NSTE ACS.  
1.1 NSTE-ACS 
Acute coronary syndromes without ST segment elevation constitute a clinically heterogeneous 
group. Pathophysiological basis of NSTE-ACS is usually unstable atherosclerotic plaque (with 
rupture, erosions and inflammatory changes) and the presence of intracoronary thrombosis. 
Intracoronary thrombus has a high content of platelet and (unlike in STEMI) is non-occlusive 
or intermittently present. In the USA were hospitalized for ACS 1.57 million patients per 1 
year, of which 0.33 million were admitted for STEMI and 1.24 million for NSTE-ACS (0.57 mil. 
for NSTEMI and 0.67 million for UA). In the same year were performed in the U.S. 1,297,000 
coronary angiographies and 658 000 PCIs (Rosamond W et al., 2007). Based on analogous 
application of these statistics data, it can be expected the annual incidence of 5500 STEMI and 
20 600 NSTE-ACS (9500 NSTEMI) in the Slovak Republic.  
According to data from the registers of ACS, invasive diagnostics was currently performed 
in less than half of patients with NSTE-ACS (Fox KA et al., 2003, Bhat DL et al., 2004, Kovar 
F et al., 2010). Assessment of the benefits of invasive management strategy in NSTE-ACS 
based on the data from randomized trials is difficult because of number of reasons. High 
proportion of patients originally enrolled in the conservative arm is then treated invasively 
and in addition, there were significant differences in the timing of invasive diagnosis in 
individual studies  (less than 2.5 hours to 7 days)) (Cannon CP et al., 2001; Fox KA et al., 
2002; Neumann FJ et al., 2003).  
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The recently published study ICTUS did not present significant difference between groups 
treated within invasive or conservative arms in terms of mortality, reinfarction or 
rehospitalization rate for period 1 and 3 year follow-up (22.7% versus 21.2%, p = 0.33). There 
was observed an increased incidence of early myocardial infarction (15% versus 10%, p = 
0.005) among invasive managed patients. During initial hospitalization, however, 76% of 
patients in the invasive group and 40% of patients scheduled for conservative treatment 
underwent revascularization procedure (Hirsh A et al., 2007).  
Similarly, meta-analysis of more than 4500 patients from randomized trials has suggested 
that routinely indicated coronary angiography compared with more conservative strategy 
was associated with increased incidence of early mortality (1.8% vs. 1.1%, p = 0.007) and  
combined endpoint of death and reinfarction (5.2 % vs. 3.8%, p = 0.002). Long term 
monitoring however, favored an invasive strategy with a reduction of death and reinfarction 
(12.2% versus 14.4%, p = 0.001) (Mehta SR et al., 2005).  
Some clinical trials were able to document benefit of invasive strategy in NSTE-ACS patients 
with an increased troponin level in the beginning, but not at its normal levels (Diderholm E 
et al., 2002, Lagerqvist B et al., 2006).  
In a recently published meta-analysis of more than 8300 patients with NSTE-ACS, there has 
been documented benefits of timely invasive procedure compared with conservative 
management in order to reduce mortality (4.9% vs. 6.5%, p = 0.001), nonfatal myocardial 
infarction (7.6 % vs. 9.1%, p = 0.012) over a 2 year follow-up period, without increasing risk 
of myocardial infarction within 1 month (Bavry AA et al., 2006). Reduction of mortality rate 
in the early invasive strategy was present during the 5- year follow-up periods in FRISCO II 
and RITA 3 trials as well (Fox KA et al., 2005; Lagerqvist B et al., 2006).  
2. RISC score 
As has been pointed out previously, NSTE-ACS is a heterogeneous group of diseases. 
Coronary angiography can reveal severe stenosis of one or more coronary arteries, 
narrowing of the left main coronary artery, presence of intracoronary thrombi (FRISC II 
investigators, 1999; Kovar F et al., 2003, 2004). These facts reflect current recommendations 
of the European Society of Cardiology (ESC), which emphasize the need for early (and 
repeated as necessary) risk stratification in patients with NSTE-ACS (Bassand JP et al.,  
2007). 
2.1 GRACE score  
The GRACE (Global Registry of acute coronary events) risk score takes into account age, 
heart rate, systolic blood pressure, serum creatinine level, Killip class on admission, need for 
resuscitation for cardiac arrest, presence of ST segment depression and increased values of 
of myocardial necrosis markers (Eagle KA et al., 2004; Fox KA et al., 2006). GRACE score is 
based on the analysis of a large unselected population from an international registry of all 
ACS (STEMI and NSTEMI). Evaluated risk factors show independent predictive value for 
both hospital and 6- month mortality (tab. 1).  
2.2 TIMI score  
The TIMI (Thrombolysis in myocardial infarction) risk score assesses anamnestic variables 
(age ≥ 65 years,  ≥ 3 risk factors of ischemic heart disease, known coronary artery stenosis > 
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Risk score 
(Tertils) 
GRACE 
risk score 
Hospital 
mortality 
(%) 
Mortality 
within 6 months (%) 
 low < 108 <1 <3 
 mean 109-140 1-3 3-8 
 high > 140 > 3 > 8 
Table 1. Hospital and six month mortality rate depending on the GRACE risk score     
 
TIMI RISK SCORE
VARIABLE
POINT 
age ≥ 65 years 1
≥ 3 risk factors for vascular disease 1
known coronary artery stenosis > 50% 1
use of aspirin in the last 7 days 1
severe angina within 24 hours 1
ST segment deviations > 0.5 mm 1
positive markers of necrosis 1
Risk score 0-7
Table 2. TIMI  (Thrombolysis in myocardial infarction)  risk score parameters 
50%, aspirin therapy in the last 7 days and the actual presence of severe angina within 24 
hours, ST segment deviations > 0.5 mm and increased laboratory markers of necrosis 
(Antman EM et al., 2000). TIMI score is then the sum of individual items (value 0-7) (tab. 2).  
Its advantage is simplicity, but has not so high predictive accuracy as a comprehensive 
GRACE score (Figure 1).  
2.3 Correlation between coronary angiography findings and the TIMI risk score level 
In a retrospective study, we investigated contribution of early risk stratification to the 
invasive management timing. Population consisted from 424 consecutive NSTE-ACS 
patients (264 men and 160 women), age 26-87 years (mean age 65,75 years, median 67 years), 
referred for coronary angiography to the Ist Department of Internal medicine University 
hospital Martin during the period from December 2009 to October 2010. 
Patients with NSTE-ACS were stratified according to the TIMI risk score and based on 
achieved risk score level subsequently divided into three risk groups (Figure 2 and 3): 
1. low risk (0-2 points) 
2. intermediate risk (3-4 points) 
3. high risk (5-7 points) 
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Fig. 1. Incidence of major cardiovascular events based on TIMI risk score level 
 
 
 
51%
26% 23%
LR IR HR
 
 
Fig. 2. Risk stratification according TIMI risk score 
LR - low risk, IR - intermediate risk, HR - high risk  
Mortality, MI, urgent revascularization 
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Fig. 3. Proportion of men and women in different risk groups  
LR - low risk, IR - intermediate risk, HR - high risk 
There were more men than women in the age range bellow 65 years in all risk groups, but 
this difference was no longer present in the age ≥ 65 years (Figure 4 and 5). 
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Fig. 4. Proportion of men and women in different risk groups in age below 65 year 
LR - low risk, IR - intermediate risk, HR - high risk 
Elevated cardiac troponin was identified as most frequent parameter of the TIMI risk score 
(in 81,8% of patients). Second often parameter occurred presence of ≥ 3 risk factors for 
coronary artery disease in 60,1% patients (Figure 6).  
Frequency of risk factors for coronary artery disease rose with increasing TIMI risk score, so 
in high-risk group almost 90% of patients had ≥ 3 risk factors (Figure 7). 
On coronary angiography was assessed stenosis of:  
• main stem of left coronary artery – LMA > 50% 
• ramus interventricular anterior - RIA > 75% 
• ramus circumflexus – RCX > 75% 
(%) 
(%) 
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• arteria coronaria dextra – RCA > 75%   
• multivessel coronary artery disease – stenosis  ≥ 3 – coronary arteries 
There were more coronary arteries stenoses identified with increasing TIMI risk score 
(Figure 8). In age range ≥ 65 years in comparison with age bellow 65 year, there were 
more coronary arteries stenoses among patients with intermediate risk. This 
relationship was even more pronounced in patients in high TIMI risk score group 
(Figure 9 and 10).  
 
40
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Fig. 5. Proportion of men and women in different risk groups in age ≥ 65 year 
LR - low risk, IR - intermediate risk, HR - high risk 
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Fig. 6. Incidence of anamnestic, clinical and laboratory parameters of TIMI risk score 
RF - risk factor for atherosclerosis, CAD - known coronary artery narrowing > 50%, ASA - 
acetylsalicylic acid, AP - angina pectoris, STd - ST segment depression ≥ 0.5 mm,  Tn – 
troponin 
(%) 
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Fig. 7. Proportion of patients with ≥ 3 risk factors for coronary artery disease in different risk 
groups 
LR - low risk, IR - intermediate risk, HR - high risk 
 
 
Fig. 8. Coronary arteries stenoses in different risk groups  
LMA - left main coronary artery, RIA - ramus interventricularis anterior, RCX - ramus 
circumflexus, RCA - arteria coronaria dextra, MV - multivessel coronary artery disease 
(%) 
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Fig. 9. Coronary arteries stenoses in patients with intermediate TIMI risk score in different 
age groups 
LMA - left main coronary artery, RIA - ramus interventricularis anterior, RCX - ramus 
circumflexus, RCA - arteria coronaria dextra, MV - multivessel coronary artery disease 
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Fig. 10. Coronary arteries stenoses in patients with high TIMI risk score in different age 
groups 
LMA - left main coronary artery, RIA - ramus interventricularis anterior, RCX - ramus 
circumflexus, RCA - arteria coronaria dextra, MV - multivessel coronary artery disease 
Coronary angiography findings were negative in 25,7% of patients. While in the group with 
low risk, coronary angiography was without significant stenosis in 42,8% of patients, there 
was so in 25,5% in the intermediate risk group and in only 10,8% of patients in high risk 
group (Figure 11). Extensive involvement of coronary arteries was assessed by coronary 
angiography in intermediate and high risk groups. 
(n) 
(n) 
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Fig. 11. Proportion of patients without significant coronary artery stenosis in different TIMI 
risk group 
LR - low risk, IR - intermediate risk, HR - high risk 
3. Indication and timing of invasive diagnostics 
Depending on the risk score level, we can make decisions for the indication of invasive 
diagnostic and its timing in patients with NSTE-ACS in three modes (urgent, early  
invasively and elective) (Bassand JP et al., 2007):  
3.1 Urgent invasive strategy  
It is indicated within 2 hours in patients with high risk score. This strategy is taken in to 
account particularly in patients with:  
a. Refractory angina 
b. Recurrent angina despite intensive pharmacologic treatment with presence of deep (≥ 2 
mm) ST segment depression or deep negatives T waves on ECG 
c. Symptoms of heart failure or hemodynamic instability (incipient signs of shock) 
d. Serious arrhythmias (ventricular fibrillation or ventricular tachycardia)  
3.2 Early invasive strategy  
This strategy is considered in NSTE-ACS patients with high risk of serious ischemic events. 
Coronary angiography should be performed within 72 hours in this group.  
(%) 
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These are patients presenting with:  
a.  elevated troponin levels 
b.  dynamic ST segment or T waves changes (≥ 0.5 mm)  
c.  diabetes mellitus  
d.  reduced renal function (GFR <1 ml / s)  
e.  reduced left ventricular ejection fraction <40%  
f.  angina pectoris early after myocardial infarction  
g.  angina pectoris within 6 months after coronary intervention (PCI)  
h.  history of coronary artery bypass grafting (CABG)  
i.  medium or high risk GRACE score 
3.3 Conservative (elective) strategy  
It is indicated in those patients who meet all the following criteria: 
Are free of:  
a. Recurrence of angina pectoris 
b. Symptoms of heart failure 
c. Major arrhythmias 
d. Changes in both initial and second ECG (after 6-12 hours) 
e. Elevated troponin levels (at entrance examinations and even after 6-12 hours) 
Low risk, as assessed by GRACE or TIMI scores, supports the decision making for a 
conservative treatment. These patients should undergo an exercise test before hospital 
discharge and coronary angiography in case of inducible ischemia.  
Risk stratification of ACS patients (as recommended by the ESC) is now clearly 
recommended to identify patients with moderate to high risk of serious cardiovascular 
complications, who benefit most from both early invasive diagnosis and subsequent 
coronary arteries revascularization. In so selected risky ACS group coronary angiography 
has to be performed during index hospitalization. 
4. Effect of early treatment strategy on long-term outcomes in NSTE-ACS 
Because invasive diagnosis plays an important role in the management of NSTE-ACS, we 
decided to analyze the clinical course of patients who have been made coronary 
angiography at the beginning and by finding subsequently revascularization, and also in 
those patients who refused invasive testing (Kovar F et al., 2007).  
4.1 Patients and methods  
Prospective analysis of consecutive patients admitted to our clinic with a diagnosis of 
unstable angina or myocardial infarction without ST segment elevation. All patients 
received comprehensive standard (according to current recommendations) pharmacologic 
therapy. Within 48 hours was performed coronary angiography and further 
revascularization therapy if appropriate. Invasive diagnosis was not performed in patients 
who refused this procedure.  
Initial coronary angiography record was analyzed according to location and type of 
coronary stenosis (A, B, C),  closure of coronary artery was evaluated separately. 
Lesion type A: a short concentric stenosis, easily accessible, less calcified, without thrombus, 
without side branch involving (success rate of intervention> 85%, low risk) 
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Lesion type B: tubular 10 to 20 mm long, eccentric, with the presence of calcifications, 
involving ostium of coronary artery, bifurcation stenosis, presence of thrombus 
(intervention success rate 60-85%, moderately high risk) 
Lesion type C: diffuse stenosis> 20 mm, extremely coiled proximal segments, bifurcation 
lesions with the impossibility to access a lateral branches (success rate of intervention <60%, 
high risk) (Figure 12 a,b,c). 
During the one-year follow-up period there were assessed mortality rate, need for repeated 
hospitalization for ACS or revascularization and left ventricular ejection fraction (LVEF). 
These endpoint variables were evaluated in four groups of patiens who: 1) underwent 
percutaneous coronary intervention (PCI) or 2) surgical revascularization (CABG), 3) after 
angiography were treated conservatively or 4) refused invasive diagnostics in the beginning.  
4.2 Statistical analysis 
Any analysis of the effectiveness of the treatment was made in four groups of patients: PCI, 
CABG, conservative treatment and conservative treatment without initial invasive 
diagnosis. Two-sided Fisher's exact test in the modification of 2 x 4 was used to test 
hypotheses about the same effect of therapies. χ2 test were used for a posteriori analysis of 
categorical variables. As statistically significant we considered differences at significance 
level of P < 0,05.  
4.3 Results  
During the reporting period were for UA and NSTEMI admitted 183 patients, of which 109 
were men aged 35-84 (mean ± SD: 55,9 ± 11,6) years and 74 women aged 44-86 (mean ± SD: 
66; 5 ± 12.0) years. History and clinical variables are shown in table 3. 
 
 
Fig. 12a. Lesion type A 
www.intechopen.com
 Coronary Angiography – The Need for Improvement in Medical and Interventional Therapy 
 
28
  
   
Fig. 12b. Lesions type B 
Evaluated population of patients has been at high risk for the presence of cardiovascular 
risk factors and history of cardiovascular disease: more than 65% patients had hypertension, 
37.7% had a myocardial infarction, in nearly 20% was already performed a revascularization 
of coronary arteries in the past, 9.8% had stroke, hypercholesterolemia was present in 77% 
and diabetes mellitus in 25.7% of all patients.  
Early after hospital admission, 171 patients (93.4%) underwent coronary angiography 
and 12 (6.6%) patients refused invasive diagnostics (they were also treated 
conservatively).  
There was found in 7.6% of patients closure of coronary arteries, advanced atherosclerotic 
coronary artery stenosis (stenosis B and C) were evaluated in 67.8% patients on the initial 
angiography. Frequency of significant coronary arteries stenosis (ramus interventricularis 
anterior, ramus circumflexus, right coronary artery) was similar (37.4%, 32.8%, 
respectively 22 %), significant impairment of left main coronary artery was present in 7% 
of patients.  
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Fig. 12c. Lesions type C 
Subsequent coronary revascularization underwent 72.1% of patients (mostly PCI was 
performed), 21.3% were treated conservatively after angiography and in 6.6% patients was 
not coronary angiography performed in the beginning.  
Table 4. shows the presence of analyzed clinical parameters in different groups during a 
one-year follow-up, their comparison is in table 5.  
There was a trend to higher mortality rate and more frequent need for both repeat 
hospitalization or revascularization for ACS among patients treated conservatively without 
angiography at the beginning in comparison with invasive strategy group. LVEF> 50% 
occurred significantly more in patients treated according angiographic findings compared 
with patients without initial coronary angiography. The different incidence reached the 
highest statistical significance when compared group of patients without coronary 
angiography with patients treated with PCI (a posteriori analysis).  
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  n % 
 No. of patients  183 100,0 
 men  109 56,3 
 hypertension  120 65,6 
 hypercholesterolemia  141 77,0 
 History of MI  69 37,7 
 History of PCI  23 12,6 
 History of CABG  13 7,1 
 LV insufficiency  39 21,3 
 history of CVD +  56 30,6 
 DM  47 25,7 
 History of ictus  18 9,8 
Cigarette smoking 41 22,4 
 Obesity (BMI ≥ 30)  63 34,4 
Table 3. History and clinical variables 
MI – myocardial infarction, PCI – percutaneous coronary intervention, CABG – bypass 
grafting, LV – left ventricle, DM – diabetes mellitus, CVD – cardiovascular disease 
 
1 – year follow up 
 
PCI 
(n = 84) 
CABG 
(n =48) 
Without 
revascularization
(n = 39)
Without 
angiography 
(n = 12) 
 Parameter n % n % n % n % 
 Mortality rate 4 4,8 2 4,2 4 10,3 3 25,0 
 Rehospitalization for
 UA / PCI /   MI
11 13,1 5 10,4 6 15,4 5 41,7 
 LVEF ≥ 50% 71 84,5 31 64,6 22 56,4 4 33,3 
 LVEF <50% 13 15,5 17 35,4 17 43,6 8 66,7 
Table 4. 1-year follow up 
UA – unstable angina, PCI – percutaneous coronary intervention, MI – myocardial 
infarction, LVEF – left ventricle ejection fraction 
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PCI 
(N = 84)
CABG
(N = 48)
Without 
Revasc. 
(N = 39) 
Without 
angiography 
(N = 12) 
P 
value 
 mortality rate 4 (4,8) 2 (4,2) 4 (10,3) 2 (16,7) 0,2047 
 repeat 
 hospitalization 
11 (13,1) 5 (10,4) 6 (15,4) 5 (41,7) 0,0811 
 LVEF ≥ 50% 71 (84,5) 31 
(64,6)
22 (56,4) 4 (33,3) 0,0001 
Table 5. Comparison of applied therapeutic strategies during 1 year follow up 
PCI – percutaneous coronary intervention, LVEF – left ventricle ejection fraction, CABG – 
bypass grafting 
5. SLOVACS registry of acute coronary syndromes  
Slovak registry of acute coronary syndromes (SLOVACS) deals with data collection and 
evaluation of patients hospitalized for ACS since 2007 year. Sheets with information about 
of ACS patients hospitalization are sent by physicians from various hospital departments 
(coronary units, intensive care units, cardiology or internal departments).  
5.1 Objective  
The aim of this analysis is to provide an assessment of management of patients with NSTE-
ACS in Slovakia in 2008 year and to assess compliance of fair practice and official 
recommended guidelines for diagnosis and treatment of ACS without ST segment 
elevations. The source data for analysis were drawn from the registry of acute coronary 
syndromes SLOVACS (Kovar F et al., 2010).  
5.2 Methods  
SLOVACS registry is dedicated to both systematic data collection and subsequent analysis of 
ACS in Slovakia since 2007 year. This registry is organizationally arranged by Slovak Society of 
Cardiology (SKS) and National Health Information Centre (NHIC) (Studencan M et al., 2008). 
Data on patients with acute coronary syndrome are recruited from sheets of ACS, which are 
completed and electronically transmitted to the NHIC by physicians from different departments 
(internal, cardiology, intensive care units, coronary units), where is the patient hospitalized with 
a diagnosis of ACS. This activity is supervised by the special regional coordinators. 
In this particular analysis we evaluated data results in patients with NSTE-ACS and non-
specified ACS. If the detailed and clear ECG diagnosis and accurate categorization of ACS at 
admission was not possible, this ACS was marked like non-specified ACS (presence of left 
bundle branch block, after repeated myocardial infarction, repolarization changes in left 
ventricular hypertrophy). 
In NSTE-ACS population were assessed selected history variables, age and gender of 
patients. There was made an analysis of given therapy, with special attention to invasive 
diagnosis of ACS and revascularization therapy (PCI or surgical). It was also evaluated 
hospital mortality and subsequent analysis of the causes of death.  
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5.3 Statistical analysis 
Descriptive statistics were calculated for patient groups of men and women in the categories 
of UA / NSTEMI-ACS and non-specified ACS. Averages and standard deviations (SD) were 
calculated for continuous variables and for categorical variables were calculated frequency 
distribution or percentage was used respectively. To estimate the statistical significance of 
differences, Student's t-test for continuous variables and Fisher's exact test for categorical 
variables were used. For statistically significant differences the significance level of P < 0,05 
was determined. Statistical analysis was performed in SPSS, Windows version 13.0 (SPSS 
Inc., Chicago, IL, USA).  
5.4 Results 
There were reported to NHIC 3047 hospitalization for NSTE-ACS and 799 hospitalizations for 
non-specified ACS during period 1.1.2008 - 31.12.2008. For all subtypes of ACS, women were 
on average older than men and men diagnosed with NSTE-ACS were significantly older 
compared with a group of men in the STEMI-ACS (66 ± 12 vs. 61 ± 12, P < 0,001). Tab. 6 shows 
the proportion of patients in different types of ACS, taking into account age and sex. 
 
Number of cases                                           Mean age (years± SD) 
 Total Men Women Total Men Women 
 ACS 6 241 3816 (61.1%) 2425 (38.9%) 67 ± 12 64 ± 12 71 ± 11 a 
 STEMI 2415 (38.7%) 1593 (66.0%) 822 (34.0%) 64 ± 13 61 ± 12 b 71 ± 12 a 
 UP / NSTEMI 3047 (48.8%) 1799 (59.0%) 1268 (41.0%) 68 ± 12 66 ± 12 71 ± 11 a 
 Non-spec. ACS 799 (12.5%) 444 (55.6%) 355 (44.4%) 68 ± 12 65 ± 13 71 ± 11 a 
Table 6. Distribution of ACS by type, age and sex 
a P < 0,001 men vs women, b P < 0,001 men with STEMI vs men with NAP/NSTEMI, ACS - 
acute coronary syndrome, STEMI - acute coronary syndrome with ST segment elevation, UA / 
NSTEMI - Unstable angina pectoris / myocardial infarction without ST segment elevations 
5.5 Anamnestic data  
Each patient was systematically assessed with respect to the evidence of hypertension, 
diabetes mellitus  type I or II, history of stroke. As is apparent from the graphs 12 and 13, in 
both types of ACS was significantly often present arterial hypertension (80.1% respectively 
78.3%) and diabetes mellitus  type II (30.3% respectively 27.1%) and 12.1% of patients has 
history of stroke (Figures 13 and 14). 
Occurence of concominat diseases in patinens with non-STE-ACS was similar in both 
SLOVACS registries 2007 and 2008 years (Figure 15). 
5.6 Revascularization therapy  
Among 3047 patients with NSTE-ACS coronary angiography was performed in 943 patients 
(30.9%) during index hospitalization, 799 patients (26.2%) were sent to catheterization 
laboratory from other institutions. Of the 799 patients with non-specified ACS was 
performed coronary angiography in 284 patients (35.5%). To invasive diagnosis were 
referred 187 patients (23.4%) from other hospitals (without catheterization facilities).  
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Fig. 13. Occurrence of major diseases observed in patients with UA / NSTEMI 
DM - diabetes mellitus, UA / NSTEMI - Unstable angina pectoris / myocardial infarction 
without ST segment elevations 
 
 
Fig. 14. Occurrence of major diseases observed in patients with non-specified ACS 
DM - diabetes mellitus, ACS - acute coronary syndrome 
Percutaneous coronary intervention (PCI) was performed in 409 patients (13.4%) with 
NSTE-ACS and 50 patients (6.3%) with non-specified ACS. During PCI was in NSTE-ACS 
implanted 370 intracoronary bar metal stents and 76 (20.5%) drug eluting stents. In non-
specific ACS patients were during intervention procedures implanted 111 stents, including 
17 (15.3%) drug eluting stents.  
Surgical revascularization (CABG) was performed during hospitalization for NSTE-ACS in 
165 patients (5.4%) or was scheduled electively for additional 128 patients (4.2%). Together 
was cardiac therapy planned for 293 patients (9.6%). In case of non-specific ACS were 
performed CABG immediately in 27 patients (3.5%), and planned later in 30 pts. (3.8%), 
together was cardiac revascularization indicated in 57 patients (7.3%).  
5.7 Pharmacological treatment  
SLOVACS registry systematically monitor the use of antiplatelet therapy (aspirin, 
clopidogrel), platelet glycoprotein IIb / IIIa receptor blockers, unfractionated and low 
molecular weight heparin, beta blockers, angiotensin converting enzyme inhibitors and 
statins. Use of individual drug groups shows table 7 and 8. 
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Fig. 15. Comparison of incidence of major diseases in patients with NSTE-ACS in both 
SLOVACS registry 2007 and 2008 year 
 
 Pharmacological treatment  N (%) 
 Aspirin  2753 (90.4%) 
 GP IIb / IIIa  70 (2.3%) 
 Clopidogrel  2636 (86.5%) 
 Beta-blocker  2471 (81.1%) 
 Heparin (UFH)  729 (23.9%) 
 Heparin (LMWH)  2267 (74.4%) 
 ACE inhibitor  2410 (79.1%) 
 Statin  2403 (78.9%) 
Table 7. Concomitant treatment studied in patients with UA / NSTEMI 
GP - platelet glycoprotein IIb / IIIa receptor blockers, UFH - unfractionated heparin, LMWH 
- low molecular weight heparin, ACE - angiotensin converting enzyme, UA / NSTEMI - 
Unstable angina pectoris / myocardial infarction without ST segment elevation 
5.8 Hospital mortality analysis and causes of death  
In group of patients hospitalized with a diagnosis of NSTE-ACS, 109 patients died (3.6%). 
Analysis of causes of death during hospitalization for men and women in the group with 
NSTE-ACS is shown in table 9 and 10.  
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 Pharmacological treatment  N (%) 
 Aspirin  690 (88.6%) 
 GP IIb / IIIa  19 (2.4%) 
 Clopidogrel  625 (80.2%) 
 Beta-blocker  615(79.2%) 
 Heparin (UFH)  207 (26.6%) 
 Heparin (LMWH)  507 (65.1%) 
 ACE inhibitor  619 (79.5%) 
 Statin  598 (76.9%) 
Table 8. Concomitant treatment studied in patients with non-specified ACS 
GP - platelet glycoprotein IIb / IIIa receptor blockers, UFH - unfractionated heparin, LMWH 
- low molecular weight heparin, ACE - angiotensin converting enzyme, UA / NSTEMI - 
Unstable angina pectoris / myocardial infarction without ST segment elevation 
 
 Immediate cause of death  
men women
P 
N (%) N (%) 
 Proportion of all deaths 47 (2.6%) 62 (4.9%) <0.001 
 Rupture of interventricular septum 0 (0%) 1 (1.6%) 0,413 
 Higher degree AV block 0 (0%) 1 (1.6%) 0,413 
 Cardiogenic shock 15 (31.9%) 22 (35.5%) 0,011 
 Pulmonary edema 5 (10.6%) 8 (12.9%) 0,076 
 Ventricular fibrillation 3 (6.4%) 4 (6.5%) 0,206 
 Other cardiac events 19 (40.4%) 18 (29.0%) 0,087 
 Stroke  2 (4.3%) 1 (1.6%) 0,426 
 Other non-cardiac cause 3 (6.4%) 7 (11.3%) 0,049 
Table 9. The immediate cause of death in patients with UA / NSTEMI during the 
hospitalization phase  
UA / NSTEMI - Unstable angina pectoris / myocardial infarction without ST segment 
elevation, AV - atrioventricular  
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 Immediate cause of death  
men women 
P 
N (%) N (%) 
 Proportion of all deaths 20 (4.5%) 28 (8.4%) 0.017 
 Rupture of interventricular septum 0 (0%) 0 (0%) - 
 Higher degree AV block 1 (5.0%) 1 (3.4%) 0,494 
 Cardiogenic shock 7 (35.0%) 14 (50.0%) 0,021 
 Pulmonary edema 4 (20.0%) 2 (7.1%) 0,283 
 Ventricular fibrillation 2 (10.0%) 3 (10.7%) 0,271 
 Other cardiac events 4 (20.0%) 4 (14.3%) 0,261 
 Stroke  1 (5.0%) 1 (3.4%) 0,494 
 Other non-cardiac cause 1 (5.0%) 3 (10.7%) 0,195 
Table 10. The immediate cause of death in patients non-specified ACS during the 
hospitalization phase  
UA / NSTEMI - Unstable angina pectoris / myocardial infarction without ST segment 
elevation, AV - atrioventricular  
Comparison of hospital mortality data from the register SLOVACS per year  2007 and 2008 
and the Euro Heart Survey II provides figure 16. 
 
 
Fig. 16. Hospital mortality rate in patients with UA / NSTEMI ACS and non-specified ACS 
in SLOVACS registry per year 2007 and 2008 and EHS II 
UA / NSTEMI - Unstable angina pectoris / myocardial infarction without ST elevation, ACS 
- acute coronary syndrome, EHS - Euro Herat survey  
As apparent, pharmacologic treatment is administered sufficiently according guidelines. 
Few, however, were indicated glycoprotein IIb / IIIa platelet receptors blockers, which are 
applied mainly in patients during coronary intervention. Comparison with data from the 
register SLOVACS in 2007 and 2008 and Euro Heart Survey I and II is given in figure 17.  
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Fig. 17. Comparison of applied concomitant therapy for patients with UA / NSTEMI in the 
register SLOVACS 2007 and 2008 and EHS I and II 
ASA - acetylsalicylic acid, clopi – clopidogrel, IIb/IIIa - platelet glycoprotein receptor 
blocker, UFH - unfractionated heparin, LMWH - low molecular weight heparin, ACEI - 
angiotensin converting enzyme inhibitor, EHC - Euro Herat survey  
However, disappointing is the low proportion of patients with NSTE-ACS who are 
indicated for invasive diagnosis and possible subsequent coronary vessels revascularization. 
Comparison of data from the SLOVAKS registry 2007 and Euro Heart Survey II in terms of 
indications of coronary angiography and percutaneous coronary intervention in patients 
with NSTE-ACS shows figure 18. 
 
 
 
Fig. 18. Consumption of coronary angiography and PCI in patients with UA / NSTEMI 
according to the data from SLOVACS registry 2007 and 2008 and the EHS II  
SKG - selective coronary angiography, PCI - percutaneous coronary intervention, EHS - 
Euro Heart Survey  
Of patients who were not admitted to departments with the option for invasive diagnosis, 
were transferred to catheterization only 799 of 2405 patients (33.2%). Of the total number of 
admissions for NSTE-ACS, diagnostic catheterization underwent 943 (30.9%) patients, 
interventional treatment was performed in 409 patients (13.4%). These data are similar to 
data from other registries ACS (Polonski L et al., 2007).  
There is even more serious situation in the indication of patients for invasive diagnosis 
among non-specified ACS group, which has highest hospital lethality (6%)  in comparison 
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with various types of ACS. These patients are often elderly, with more significant co 
morbidity, renal insufficiency (Lev EI et al., 2003). From invasive diagnostic benefit most 
patients with high risk of cardiovascular complications.  
Patients with UA / NSTEMI represent a heterogeneous group of diseases with potentially 
serious both in-hospital course and long-term prognosis. As was found by the results of 
SLOVACS registry 2008, there is frequent co morbidity with high presence of hypertension 
and diabetes mellitus type II in patients with NSTE-ACS. Hospital mortality was 3.6%, in 
patients with NSTE-ACS and 6% in non-specified ACS, respectively. SLOVACS registry 
data confirm excellent acceptance of recommendations, relating to the combined 
pharmacological treatment of NSTE-ACS with a high administeration rate of dual 
antiplatelet therapy, beta blockers, angiotensin converting enzyme inhibitors, anticoagulant 
therapy (UFH and LMWH) and statins. In the management of NSTE-ACS would be 
desirable more frequent application of platelet glycoprotein IIb / IIIa inhibitors, especially in 
high-risk patients. Unsatisfactory low is the indication rate for invasive diagnostic 
procedures and revascularization treatment. Only 30.9% of patients with UA / NSTEMI and 
23.4% with non-specified ACS have performed selective angiography during the initial 
hospitalization. PCI was performed in 13.4% patients with NSTE-ACS and only 6.3% 
patients with non-specified ACS. SLOVACS registry results suggest the need for increased 
concentration of attention on a consistent risk stratification of patients with NSTE-ACS. In 
the case of medium or high risk of cardiovascular complications and unfavorable course, 
patients should be indicated for selective angiography and depend on finding, further 
coronary artery revascularization. Invasive diagnosis in these patients has to be conducted 
during the index hospitalization for NSTE-ACS.  
6. Impact of bleeding complications on the prognosis of NSTE-ACS  
In most cases a vulnerable plaque (with rupture or erosion) in the coronary artery with the 
presence of intracoronary platelets rich thrombus represents pathophysiologic basis of ACS. 
The key basic treatment regimen for NSTE-ACS is, therefore, antiplatelet therapy (mostly 
dual) and application anticoagulants agents (unfractionated heparin, low molecular weight 
heparin, fondaparinux, and direct thrombin inhibitors). In patients treated with PCI are 
often administered platelet IIb / IIIa receptor blocker. These combined and effective 
antithrombotic approaches significantly reduce the incidence of thrombotic complications in 
NSTE-ACS, but are often associated with an increased risk of bleeding. Recently, systematic 
attention is paid to the impact of bleeding on prognosis in patients with NSTE-ACS.  
6.1 Occurrence 
Bleeding complications can achieve varying degrees of severity. The most frequently used 
assessment is according to the TIMI (Thrombolysis in myocardial infarction) and GUSTO 
(Global utilization of streptokinase and t-PA for occluded coronary arteries) criteria (Table 
11) (Antman EM et al., 2005; GUSTO investigators, 1993).  
The incidence of major bleeding complications in the treatment of NSTE-ACS is in the range 
2-15% (OASIS-2 investigators, 1999; Ferguso JJ et al., 2004; Bhat DL et al., 2004). Frequency of 
bleeding is influenced by excessive dose antithrombotic medications, antithrombotic agents 
alternation (switching), presence of renal dysfunction, higher age of the patient and female 
gender (Alexander KP et al., 2005; Collet JP et al., 2005). European register GRACE (Global 
www.intechopen.com
 Risk Stratification and Invasive Strategy in NSTE-ACS 
 
39 
registry of acute coronary events) has identified additional independent predictors of major 
bleeding complications in NSTE-ACS patients (Table 12) (Moscucci M et al., 2003).  
 
 Hemorrhage  Characteristics of bleeding 
TIMI classification 
 Large  intracranial, decreased Hb ≥ 50 g / l 
 Small  decrease in Hb 30-50 g / l 
 Minimum  decrease in Hb <30 g / l 
GUSTO classification 
 Severe / life 
 -threatening  
intracranial or hemodynamically significant or requiring intervention 
 Medium  requiring transfusion but without hemodynamic disability 
 Slightly  does not meets the criteria for severe or moderate major bleeding 
Table 11. Assessment of severity of bleeding in acute coronary syndrome 
TIMI = Thrombolysis in myocardial infarction, GUSTO = Global utilization of streptokinase 
and t-PA for occluded coronary arteries  
 
 Parameter 
Adjusted
OR
95% CI P 
 age (increase per 10year)  1,22 1,10-1,35 0,0002 
 female sex  1,36 1,07-1,73 0,0116 
 renal insufficiency  1,53 1,13-2,08 0,0062 
 history of bleeding 2,18 1,14-4,08 0,014 
 mean BP (per 20mmHg decrease) 1,14 1,02-1,27 0,019 
 diuretic therapy  1,91 1,46-2,49 <0.0001 
 IIb / IIIa receptor blocker therapy 1,86 1,43-2,43 <0.0001 
 fibrinolysis receptor blocker 
 + IIb  / IIIa  
4,19 1,68-10,4 0,002 
 administration of inotropic agents 1,88 1,35-2,62 0,0002 
 right-sided catheterization  2,01 1,38-2,91 0,0003 
Table 12. Independent predictors of major bleeding in NSTE-ACS  
NSTE ACS = acute coronary syndrome without ST segment elevation, BP = mean blood 
pressure  
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6.2 The prognosis in patients with severe bleeding 
Significant increase of hospital mortality rate in patients with ACS and bleeding (OR 1.64, p 
<0.0001) highlighted the results from the GRACE registry, which collects data of patients 
with NSTE ACS already since  1999 year (Moscucci M et al., 2003) (Figure 19). 
 
 
 
*After adjustment for comorbidities, clinical presentation, and hospital therapies 
**p<0.001 for differences in unadjusted death rates 
Fig. 19. Association of major bleeding and an increased risk of hospital death in ACS patients 
In REPLACE (Randomized Evaluation of PCI linking angiomax to reduced clinical events) -
2 study, patients with major bleeding had 30 times higher risk of death during the 30-day 
monitoring in comparison with patients without such bleeding complications (5.2% vs. 
0.2%; p <0.001). Moreover, the multivariate analysis identified a major bleeding as the third 
strongest predictor (with renal dysfunction and heart failure) of 1-year mortality (OR 3.53, 
95% CI 1.91 to 6.53, p <0.0001) (Stone GW, 2004).  
Analysis of more than 26 000 patients from ACS studies GUSTO (Global utilization of 
streptokinase and t-PA for occluded coronary arteries) IIb, PURSUIT (Platelet glycoprotein 
IIb / IIIa in unstable angina: receptor suppression using INTEGRILIN therapy) and 
PARAGON (Platelet IIb / IIIa antagonist for the reduction of acute coronary syndrome 
events in a global organization network) shows a link between 30-day mortality and 
severity of bleeding, irrespectively of invasive procedures (Figure 20) (Rao SW et al., 2005).  
Another meta-analysis (34 000 patients) from OASIS (Organization to ASSESS strategies in 
acute ischemic syndromes) registry, OASIS-2 study and CURE (Clopidogrel in unstable angina 
to Prevent Recurrent Events) study confirmed that serious bleeding is a strong independent 
predictor of mortality, myocardial infarction and stroke (Table 13) (Eikelboom JE et al., 2006).  
Interesting results were shown by a 10-year retrospective analysis of 11 000 patients treated 
with PCI (Kinnaird TO et al., 2003). Major bleeding was confirmed as an independent risk 
factor for hospital mortality (OR 3.5, 95% CI 1.9 to 6.7, p = 0.001). Patients with bleeding 
complications had significantly higher incidence of Q-wave myocardial infarction (1.2% vs. 
0.2%, p <0.001), non Q-wave myocardial infarction (30.7% vs. 11.8%, p <0.001) and needs for 
repeat revascularization (1.9% vs. 0.3%, p <0.001) compared with the group without 
bleeding. Significantly increased risk of death was associate with bleeding by TIMI criteria 
rated as small as well (1.8% vs. 0.6%, p <0.001) (Figure 21).  
GRACE registry in 24,045 ACS patients 
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Fig. 20. Effect of bleeding severity by GUSTO criteria on 30-day mortality in patients with 
NSTE-ACS 
GUSTO = Global utilization of streptokinase and t-PA for occluded coronary arteries, NSTE-
ACS = acute coronary syndrome without ST segment elevation  
 
OASIS registry, OASIS-2 and CURE (N = 34 126)
Parameter Severe 
bleeding 
No major 
bleeding 
Adjusted HR 
(95% CI) 
P 
Mortality  12.8% 2.5% 5.37 (3,97-7,26) <0.0001 
Myocardial infarction 10.6% 4.1% 4.44 (3,16-6,24) <0.0001 
Stroke  2.6% 0.6% 6.46 (3,54-11,79) <0.0001 
Table 13. Effect of bleeding on the clinical course 
OASIS = Organization to assess strategies in acute ischemic syndromes, CURE = 
Clopidogrel in unstable angina to prevent recurrent events  
Unambiguous confirmation of the negative impact of bleeding on the both early and long-
term prognosis of patients with NSTE-ACS was brought by randomized trial OASIS-5 
(Yusuf S et al., 2006). This clinical study compared the effect of fondaparinux and 
enoxaparin in the treatment of more than 20 000 patients with NSTE-ACS. Although the 
primary efficacy endpoint (incidence of death, myocardial infarction or refractory ischemia 
to day 9) was similar in both groups (5.8% vs. 5.7%, p = ns), treatment with fondaparinux 
was associated with significantly lower incidence of bleeding complications (2.2% vs. 4.1%, 
p <0.001). Net clinical benefit, expressed the occurrence of death, myocardial infarction, 
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Fig. 21. Effect of bleeding on the hospital course in patients treated with PCI  
PCI = percutaneous coronary intervention, MACE = major cardiac events  
 
OASIS-5 (n = 20,078) 
 30 days 180 days 
Major bleeding  HR (95% CI) HR (95% CI) 
Death  5.06 (4,59-5,62) 3.16 (2,92-3,44) 
Myocardial infarction  5.01 (4,56-5,57) 2.99 (2,75-3,28) 
CMP  4.77 (3,95-6,00) 3,30 (2,82-3,97) 
Minor bleeding  HR (95% CI) HR (95% CI) 
Death  2.42 (2,03-2,97) 1.76 (1,31-2,37) 
Myocardial infarction  1.48 (1,28-1,78) 1,29 (1,15-1,48) 
CMP  1.54 (1,06-2,67) 1.48 (0,76-2,89) 
Table 14. Effect of bleeding to day 9 at 30 and 180-day course of patients with NSTE-ACS  
OASIS = Organization to ASSESS strategies in acute ischemic syndromes, stroke = stroke, 
NSTE-ACS = acute coronary syndrome without ST segment elevation  
refractory ischemia or major bleeding was more favorable in fondaparinux group (7.3% vs. 
9.0%, p <0.001). Patients with significant bleeding to 9  day, had during a long-term (30 and 
180 days) follow-up in the OASIS-5 study higher cumulative risk of mortality, myocardial 
infarction and stroke. This increased cumulative risk was present even in group of patients 
with a small bleeding (Table 14, Figure 22, 23, 24) (Budaj A et al., 2006).  
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Adjusted HR (95% CI) at day 30: 5.06 (4.59-5.62); at day 180: 3.16 (2.92-3.44) 
Fig. 22. Increase mortality rate in patients with severe bleeding at day 9 (all pts at day 30 
resp. day 180) 
 
 
Adjusted HR (95% CI) at day 30: 5.01 (4.56-5.57); at day 180: 2.99 (2.75-3.28) 
Fig. 23. Increase risk of myocardial infarction in patients with severe bleeding at day 9 (all 
pts at day 30 resp. day 180)  
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Adjusted HR (95% CI) at day 30: 4.77 (3.95-6.00); at day 180: 3.30 (2.82-3.97) 
Fig. 24. Increase risk of stroke in patients with severe bleeding at day 9 
(all pts at day 30 resp. day 180)  
6.3 The mechanisms for worsening clinical course 
There are postulated several mechanisms in connection with bleeding that could worse 
clinical course in NSTE-ACS (Table 15).  
 
 
hemodynamic consequences  
renal failure  
effect of transfusion  
prothrombotic and proinflammatory state triggered by bleeding  
need to discontinue antiplatelet and anticoagulant therapy  
 
Table 15. Postulated mechanisms of worse course during bleeding 
Serious consequence of bleeding is interruption of antithrombotic therapy. Clinically 
significant bleeding actually required discontinuation of anticoagulant and antiplatelet 
therapy until resolution. In the case of small transition bleeding is often possible to continue 
this therapy (Bassand JP et al., 2007).  
Application of blood transfusion improves the prognosis of elderly patients with acute 
myocardial infarction and hematocrit <30% (Wu WC et al., 2001). However, in the 
hematocrit values > 33% there was not demonstrated the usefulness of a blood transfusion. 
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By contrast, in several clinical trials and meta-analysis, the administration of blood 
transfusion was associated with increased mortality, higher incidence of myocardial 
infarction and refractory ischemia (Sabatine MS et al., 2005; Rao SW et al., 2004) (Figure 25).  
 
 
 
Adjusted for baseline characteristics, bleeding and transfusion propensity and nadir hematocrit 
Fig. 25. Association of blood transfusion with an increased 30-day mortality in UA/NSTEMI 
patients 
On the worsening clinical course in patients with NSTE-ACS after transfusion 
administration may participate:  
a. erythrocyte damage 
b. influence the metabolism of NO in blood storage 
c. impaired release of oxygen from hemoglobin in the reduction content of 2,3 -  
difosfoglycerate in erythrocytes 
d. increase inflammatory mediators (Fransen SV et al., 2008)  
Accurate cut-off level of hemoglobin and hematocrit for indication of blood transfusion in 
patients with NSTE-ACS are not provided. According to current recommendations of the 
European Society of Cardiology transfusion is not indicated for hemoglobin> 80g / l or 
hematocrit> 25%, provided that anemia is a hemodynamically well tolerated (Bassand JP et 
al., 2007).  
6.4 Prevention of bleeding complications  
Given the demonstrated risk of severe clinical events associated with bleeding and 
administration of blood transfusions, it is extremely important to use in patients with NSTE-
ACS all available measures in bleeding prevention. It is necessary to focus particularly  
on:  
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• choice of safe drug (fondaparinux in OASIS-5 study)  
• appropriate dosage (taking into account age, gender, creatinine clearance)  
• duration of antithrombotic therapy  
• timing of early invasive treatment  
• choice of arterial access  
• combination of anticoagulant and antiplatelet therapy to choose only by certified    
indications  
Prevention of bleeding complications is also important in terms of reducing hospital costs 
for treatment of NSTE-ACS. As shown by economic analysis of the GUSTO IIb study, with 
an increase in severity of bleeding, there is prolonged hospitalization and rising financial 
costs. Length of hospitalization for NSTE-ACS without bleeding was 5.4 days, with slight 
bleeding 6.9, with moderate 15.0 days, and severe bleeding 16.4 days (p <0.01). Financial 
cost of hospitalization in each group significantly increased as follows: 14 282 USD vs. 21 
674 USD vs. 45 798 USD vs. 66 564 USD (p <0.01) (Rao SV et al., 2008).  
7. Conclusion 
In addition to a comprehensive pharmacologic treatment of NSTE-ACS, which includes the 
combined antiplatelet regimens (aspirin, clopidogrel, platelet receptor IIb / IIIa blockers) 
and effective anticoagulant therapy, plays an important role early invasive diagnosis and by 
finding subsequent coronary artery revascularization. From invasive procedures benefit 
most high risk patients with NSTE-ACS, who undergoing PCI. Early invasive strategy is for 
this risk group of patients safe and is associated with long-term favorable clinical course and 
substantially influence prognosis.  
There is very important in NSTE-ACS patients risk stratification at the beginning and 
according to the assessed risk scores subsequent decision for urgent or early invasive 
strategy. In low-risk NSTE-ACS is indicated stress test and in case of inducible ischemia is 
than followed by coronary angiography before hospital discharge.  
Patients with NSTE-ACS represent a risk population with an increased incidence of ischemic 
and bleeding complications. Bleeding events significantly affect both short and long-term 
prognosis of patients with NSTE-ACS. This is why it is necessary in the global risk 
stratification of NSTE-ACS a careful assessment of the risk of bleeding. Balanced assessment 
of the risk for both thrombotic and bleeding complications allows then to select optimal 
diagnostic and therapeutic management of patients with NSTE-ACS.  
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